Patent ID: 9656957
Date: 2017-05-23
CPC Classifications: A61K,C07D

Claim:
1. A method of treating a cannabinoid receptor-mediated disease or disorder comprising administering to a subject in need thereof a therapeutically effective amount of a hydrazone compound or a pharmaceutically-acceptable salt thereof, the cannabinoid receptor-mediated disease or disorder selected from the group consisting of glaucoma, diabetes, melanoma, lymphoma, glioma, inflammation, cardiovascular disease, liver fibrosis, osteoporosis, acne, psoriasis, allergic contact dermatitis, pruritis, anxiety, demyelination, spasticity and tremor, Tourette's, Parkinson's disease, multiple sclerosis, stroke, intraocular pressure, diarrhea and nausea, the hydrazone compound comprising a compound of structural Formula I: or a salt or prodrug thereof, wherein: R